Profound Medical reports preliminary Q3 revenue $5.2-5.3M, up 84-87% YoY

Profound Medical Corp.

2025-Q3 EPS reported $1.14 revenue$10,121,000

Preliminary unaudited Q3 2025 revenue of $5.2-5.3M vs $2.8M in Q3 2024, growth 84-87%.
Gross margin expected ~72% compared to 64% in prior-year period.
TULSA-PRO installed base grew to 67 from 60; full-year target of at least 75 systems.
Full Q3 2025 results and conference call scheduled for November 13, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.